Study of Non-Coding RNA Molecule MRPL46 (G26589)

Target Name: MRPL46

NCBI ID: G26589

MRPL46

Study of Non-Coding RNA Molecule MRPL46

MRPL46 (C15orf4) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and biology make it an intriguing target for researchers to study.

The molecule has a length of 21.4 kilobases and consists of 11 exons. It is located on chromosome 15, which is one of the 23 pairs of human chromosomes. The gene encoding MRPL46 is located on the short arm of chromosome 15, specifically at position 129.950.

MRPL46 is a RNA molecule that plays a role in regulating gene expression. It is a non-coding RNA molecule, which means it does not contain any amino acids, but it can interact with protein molecules to regulate the activity of those proteins. This interaction between MRPL46 and proteins is known as post-transcriptional regulation.

One of the unique features of MRPL46 is its structure. It has a stem-loop structure, which is a type of loop that is composed of a series of nitrogenous base pairs that are connected by a phosphate group. This type of loop is called a stem-loop because it is the foundation of the molecule and appears to be the structural unit.

The stem-loop region of MRPL46 is rich in conservatism, which means that it is highly resistant to changes in the environment. This stability is important for the molecule to function as a drug target because changes in the stem-loop region can make it more vulnerable to attack by proteins that could potentially inhibit its function.

In addition to its unique structure, MRPL46 is also a promising biomarker for cancer. Cancer is a disease that affects the cells of the body and can be a difficult treatment to manage. Because MRPL46 is involved in regulating gene expression, it is possible that changes in the stem-loop region could be associated with the development or progression of cancer. This makes it an attractive target for researchers to study in order to better understand the role of this molecule in disease.

One of the potential ways to study MRPL46 is through RNA interference (RNAi) experiments. RNAi is a technique that involves using small interfering RNA (siRNA) to knockdown the expression of a specific gene. By using RNAi to reduce the amount of MRPL46 in cells , researchers can study its effects on gene expression and determine if it is a potential drug target or biomarker for cancer.

Another way to study MRPL46 is through mass spectrometry (MS). MS is a technique that involves identifying the proteins that interact with a specific target protein using antibodies. By using MS to identify proteins that interact with MRPL46, researchers can study its functions in more detail and determine if it is a potential drug target or biomarker for cancer.

MRPL46 has also been shown to interact with several proteins that are involved in various cellular processes, including cell signaling, DNA replication, and apoptosis. This suggests that it may be a useful target for drugs that target these processes. For example, one potential drug that has been shown to interact with MRPL46 is doxorubicin, which is a chemotherapy drug that is used to treat various types of cancer. doxorubicin works by inhibiting the activity of topoisomerase II, which is a protein that plays a role in the replication of DNA. By inhibiting this protein, doxorubicin can inhibit the growth and spread of cancer cells.

In addition to its potential as a drug target, MRPL46 is also a potential biomarker for cancer. Its stem-loop structure makes it rich in conservatism, which makes it more resistant to changes in the environment. This stability is important for the molecule to function as a biomarker because changes in the stem-loop region could make it less reliable. However, researchers have shown that changes in the stem-loop region are associated with the development and progression of cancer. This makes MRPL46 an attractive target for

Protein Name: Mitochondrial Ribosomal Protein L46

The "MRPL46 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MRPL46 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets